NZ752353A - Antifungal dry powders - Google Patents
Antifungal dry powdersInfo
- Publication number
- NZ752353A NZ752353A NZ752353A NZ75235317A NZ752353A NZ 752353 A NZ752353 A NZ 752353A NZ 752353 A NZ752353 A NZ 752353A NZ 75235317 A NZ75235317 A NZ 75235317A NZ 752353 A NZ752353 A NZ 752353A
- Authority
- NZ
- New Zealand
- Prior art keywords
- dry powders
- antifungal
- antifungal dry
- itraconazole
- leucine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662408376P | 2016-10-14 | 2016-10-14 | |
| PCT/US2017/056497 WO2018071757A1 (en) | 2016-10-14 | 2017-10-13 | Antifungal dry powders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ752353A true NZ752353A (en) | 2023-06-30 |
Family
ID=60186406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ752353A NZ752353A (en) | 2016-10-14 | 2017-10-13 | Antifungal dry powders |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11116722B2 (enExample) |
| EP (1) | EP3525759A1 (enExample) |
| JP (1) | JP7085538B2 (enExample) |
| KR (1) | KR102408798B1 (enExample) |
| CN (1) | CN109996536B (enExample) |
| AU (1) | AU2017341815B2 (enExample) |
| CA (1) | CA3039485A1 (enExample) |
| IL (1) | IL265913B2 (enExample) |
| MX (1) | MX388733B (enExample) |
| NZ (1) | NZ752353A (enExample) |
| RU (1) | RU2766086C2 (enExample) |
| WO (1) | WO2018071757A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2640921C2 (ru) * | 2010-09-29 | 2018-01-12 | Пулмэтрикс, Инк. | Катионы одновалентных металлов сухих порошков для ингаляций |
| EP3781164A1 (en) * | 2018-04-18 | 2021-02-24 | Cipla Technologies LLC | Methods of treating fungal infections |
| JP7549534B2 (ja) * | 2018-04-18 | 2024-09-11 | パルマトリックス オペレーティング カンパニー，インコーポレイテッド | イトラコナゾールを含む肺内投与のための抗真菌配合物 |
| WO2021092349A1 (en) * | 2019-11-08 | 2021-05-14 | Scynexis, Inc. | Lipid-based formulations of scy-078 salts |
| CN111658610B (zh) * | 2020-07-31 | 2022-05-24 | 上海方予健康医药科技有限公司 | 一种供雾化器用的三氮唑类抗真菌药物的混悬液 |
| IT202000030443A1 (it) | 2020-12-10 | 2022-06-10 | Zambon Spa | Polvere inalabile comprendente voriconazolo in forma cristallina |
| IT202000030437A1 (it) | 2020-12-10 | 2022-06-10 | Zambon Spa | Metodo per la realizzazione di una polvere inalabile comprendente voriconazolo |
| MX2023010120A (es) * | 2021-03-03 | 2023-10-30 | Pulmatrix Operating Co Inc | Formulaciones de polvo seco de dihidroergotamina y metodos de uso. |
| WO2023086013A2 (en) * | 2021-11-09 | 2023-05-19 | Agency For Science, Technology And Research | A salt-based antifungal powder platform formulation for aerosolization |
| WO2023122522A1 (en) * | 2021-12-20 | 2023-06-29 | Pulmatrix Operating Company, Inc. | Dry powder formulations of narrow spectrum kinase inhibitors |
| KR20250053839A (ko) | 2022-06-21 | 2025-04-22 | 호비온 사이언티아 리미티드 | 당과 지질 복합입자를 포함하는 흡입용 결정형 약학 조성물 및 제조방법 |
| US20260048049A1 (en) | 2022-08-18 | 2026-02-19 | Pulmatrix Operating Company, Inc. | Methods for treating cancer using inhaled angiogenesis inhibitor |
| CA3266383A1 (en) | 2022-08-31 | 2024-03-07 | Pulmatrix Operating Company, Inc. | METHODS FOR USING DRY ITRACONAZOLE POWDERS |
| AU2024345688A1 (en) * | 2023-09-20 | 2026-04-09 | Cystetic Medicines, Inc. | Use of a dry powder inhaler to treat or prevent pulmonary fungal infections |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4069819A (en) | 1973-04-13 | 1978-01-24 | Societa Farmaceutici S.P.A. | Inhalation device |
| US4097620A (en) | 1977-05-02 | 1978-06-27 | Xerox Corporation | Magnetic toner particle coating process |
| US4916134A (en) | 1987-03-25 | 1990-04-10 | Janssen Pharmacuetica N.V. | 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones |
| IT1228459B (it) | 1989-02-23 | 1991-06-19 | Phidea S R L | Inalatore con svuotamento regolare e completo della capsula. |
| US7473433B2 (en) * | 2000-12-21 | 2009-01-06 | Nektar Therapeutics | Pulmonary delivery of polyene antifungal agents |
| US8404217B2 (en) | 2000-05-10 | 2013-03-26 | Novartis Ag | Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use |
| US6448401B1 (en) * | 2000-11-20 | 2002-09-10 | Bristol-Myers Squibb Company | Process for water soluble azole compounds |
| ITMI20010357U1 (it) | 2001-06-28 | 2002-12-30 | Plastiape Spa | Dispositivo inalatore |
| EP1581182A2 (en) | 2002-12-31 | 2005-10-05 | Nektar Therapeutics | Aerosolizable pharmaceutical formulation for fungal infection therapy |
| KR20060015316A (ko) | 2003-05-28 | 2006-02-16 | 넥타르 테라퓨틱스 | 아미노산 및/또는 인지질로 부분 또는 완전 코팅된수불용성 활성제 미립자의 제조를 위한 알코올성 수용액의분무 건조법 |
| JP2007508240A (ja) | 2003-07-22 | 2007-04-05 | バクスター・インターナショナル・インコーポレイテッド | 低分子量有機分子の小球状粒子ならびにその調製方法および使用方法 |
| GB0327723D0 (en) | 2003-09-15 | 2003-12-31 | Vectura Ltd | Pharmaceutical compositions |
| US8513204B2 (en) | 2004-06-21 | 2013-08-20 | Novartis Ag | Compositions comprising amphotericin B, mehods and systems |
| US9061027B2 (en) | 2004-08-27 | 2015-06-23 | Board Of Regents, The University Of Texas System | Enhanced delivery of drug compositions to treat life threatening infections |
| GB0425758D0 (en) | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
| ITMI20051999A1 (it) | 2005-10-21 | 2007-04-22 | Eratech S R L | Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita' |
| WO2007092088A1 (en) | 2005-12-28 | 2007-08-16 | Nektar Therapeutics | Compositions comprising amphotericin b |
| CN101495096A (zh) * | 2006-05-30 | 2009-07-29 | 伊兰制药国际有限公司 | 纳米微粒泊沙康唑制剂 |
| BRPI0716658A2 (pt) | 2006-08-11 | 2015-02-10 | Panacea Biotec Ltd | Partículas para distribuição de ingredientes ativos, processo de fabricação e suas composições |
| EP2227085A4 (en) | 2007-12-06 | 2013-10-09 | Berg Pharma Llc | INGREDIBLE COMPOSITIONS WITH INCREASED BIOLOGICAL AVAILABILITY |
| CA2723314C (en) | 2008-02-13 | 2017-01-10 | The Board Of Regents, The University Of Texas System | Templated open flocs of anisotropic particles for enhanced pulmonary delivery |
| EP2095816A1 (en) | 2008-02-29 | 2009-09-02 | Schlichthaar, Rainer, Dr. | Nanosuspension with antifungal medication to be administered via inhalation with improved impurity profile and safety |
| EP2172193A1 (en) | 2008-10-02 | 2010-04-07 | Capsulution Nanoscience AG | Improved nanoparticulate compositions of poorly soluble compounds |
| CA2809666C (en) * | 2010-08-30 | 2020-09-22 | Michael M. Lipp | Dry powder formulations and methods for treating pulmonary diseases |
| EP2723452A2 (en) | 2011-06-22 | 2014-04-30 | Vyome Biosciences Pvt Ltd | Conjugate-based antifungal and antibacterial prodrugs |
| EP2601973A1 (en) * | 2011-12-09 | 2013-06-12 | Laboratoires SMB SA | Dry powder formulation of azole derivative for inhalation |
| US20180369513A1 (en) | 2012-02-21 | 2018-12-27 | Respira Therapeutics, Inc. | Powder dispersion devices and methods |
| WO2013132457A2 (en) | 2012-03-07 | 2013-09-12 | National Institute Of Pharmaceutical Education And Research (Niper) | Nanocrystalline solid dispersion compositions and process of preparation thereof |
| WO2014106727A1 (en) | 2013-01-03 | 2014-07-10 | Vectura Limited | Inhaler and formulation |
| US20150366890A1 (en) | 2013-02-25 | 2015-12-24 | Trustees Of Boston University | Compositions and methods for treating fungal infections |
| CA2907566C (en) * | 2013-04-01 | 2023-08-22 | Pulmatrix, Inc. | Tiotropium dry powders |
| CN104398497B (zh) * | 2014-10-29 | 2017-11-24 | 中山大学 | 伊曲康唑吸入粉雾剂及其制备方法 |
| CN107427650A (zh) * | 2015-01-14 | 2017-12-01 | 瑞必治公司 | 粉末分散方法和装置 |
-
2017
- 2017-10-13 EP EP17791259.9A patent/EP3525759A1/en active Pending
- 2017-10-13 KR KR1020197013649A patent/KR102408798B1/ko active Active
- 2017-10-13 US US16/341,152 patent/US11116722B2/en active Active
- 2017-10-13 AU AU2017341815A patent/AU2017341815B2/en active Active
- 2017-10-13 IL IL265913A patent/IL265913B2/en unknown
- 2017-10-13 CA CA3039485A patent/CA3039485A1/en active Pending
- 2017-10-13 WO PCT/US2017/056497 patent/WO2018071757A1/en not_active Ceased
- 2017-10-13 CN CN201780063648.5A patent/CN109996536B/zh active Active
- 2017-10-13 RU RU2019114112A patent/RU2766086C2/ru active
- 2017-10-13 NZ NZ752353A patent/NZ752353A/en unknown
- 2017-10-13 MX MX2019004322A patent/MX388733B/es unknown
- 2017-10-13 JP JP2019520036A patent/JP7085538B2/ja active Active
-
2023
- 2023-12-29 US US18/400,054 patent/US20240285523A1/en not_active Abandoned
-
2025
- 2025-02-13 US US19/052,958 patent/US20250221928A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112019007459A2 (pt) | 2019-07-16 |
| WO2018071757A1 (en) | 2018-04-19 |
| RU2019114112A3 (enExample) | 2021-02-12 |
| US20250221928A1 (en) | 2025-07-10 |
| US20200129428A1 (en) | 2020-04-30 |
| RU2019114112A (ru) | 2020-11-16 |
| EP3525759A1 (en) | 2019-08-21 |
| CN109996536B (zh) | 2023-03-07 |
| MX2019004322A (es) | 2019-12-11 |
| CA3039485A1 (en) | 2018-04-19 |
| AU2017341815A1 (en) | 2019-05-02 |
| KR20190068591A (ko) | 2019-06-18 |
| RU2766086C2 (ru) | 2022-02-07 |
| KR102408798B1 (ko) | 2022-06-13 |
| IL265913B1 (en) | 2024-03-01 |
| IL265913A (en) | 2019-06-30 |
| AU2017341815B2 (en) | 2023-06-15 |
| US11116722B2 (en) | 2021-09-14 |
| JP7085538B2 (ja) | 2022-06-16 |
| MX388733B (es) | 2025-03-20 |
| US20240285523A1 (en) | 2024-08-29 |
| IL265913B2 (en) | 2024-07-01 |
| CN109996536A (zh) | 2019-07-09 |
| JP2019534270A (ja) | 2019-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX388733B (es) | Polvos secos antifungicos. | |
| ZA201801657B (en) | Adeno-associated virus factor viii vectors, associated viral particles and therapeutic formulations comprising the same | |
| PL3668937T3 (pl) | Kompozycje i zastosowania Z-1-chloro-2,3,3,3-tetrafluoroprop-1-enu | |
| EP3518692A4 (en) | EVAPORABLE TOBACCO WAX COMPOSITIONS AND CONTAINERS THEREFOR | |
| EP4438132A3 (en) | Stable microcapsule compositions | |
| IL263355A (en) | Nicotine particles and preparations | |
| GB201508671D0 (en) | Aerosol generating material and devices including the same | |
| GB201508670D0 (en) | Aerosol generating material and devices including the same | |
| IL266526A (en) | Recombinant virus, preparations containing it and its uses | |
| TW201637267A (en) | Powder, electrode and battery comprising such a powder | |
| IL265770A (en) | Conjugates are intended for sstr and particles and their formulations | |
| SG11202105540YA (en) | 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same | |
| EP3222268A4 (en) | Powder dispersant, powder-dispersed composition containing same, and cosmetic | |
| IL272055A (en) | 8,1-naphthyridinone compounds and their uses | |
| IL268959A (en) | Antibodies with cystine mutation, preparations containing them and their uses | |
| IL262020B (en) | Grisiofulvin compound, preparations containing it and its uses | |
| IL263842A (en) | Tatk -cdkl5 fusion proteins, compositions, formulations, and use thereof | |
| IL271852A (en) | Solid powder supplements containing quercetin, a process for their preparation and their formulations | |
| GB202002129D0 (en) | stable freshening compositions and products comprising the same | |
| MX2016017142A (es) | Dispersion solida de allisartan isoproxilo y composicion farmaceutica que comprende la misma. | |
| WO2016036960A8 (en) | Therapeutic nanoparticles and related compositions, methods and systems | |
| WO2015139020A3 (en) | Vaccine compositions and methods for restoring nkg2d pathway function against cancers | |
| HUE058099T2 (hu) | Száraz por alakú ketamin készítmény depresszió kezelésében történõ alkalmazásra pulmonáris adagolással | |
| CL2018002542A1 (es) | Na2-imp deshidratada como agente antiaglomerante | |
| WO2017090038A3 (en) | Particulate photoinitiators and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 OCT 2025 BY THOMSON REUTERS Effective date: 20240903 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 OCT 2026 BY THOMSON REUTERS Effective date: 20250901 |